# Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

> **NCT06288373** · PHASE2,PHASE3 · RECRUITING · sponsor: **Tongji Hospital** · enrollment: 440 (estimated)

## Conditions studied

- Cervical Cancer
- Locally Advanced Cervical Cancer
- Concurrent Chemoradiotherapy
- Neoadjuvant Chemoimmunotherapy

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Cisplatin
- **DRUG:** Nab paclitaxel
- **PROCEDURE:** Radical surgery
- **RADIATION:** external beam radiation therapy (EBRT) + brachytherapy
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT06288373
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-22
- **Primary completion:** 2031-03-01
- **Final completion:** 2031-03-01
- **Target enrollment:** 440 (ESTIMATED)
- **Last updated:** 2024-10-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06288373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06288373, "Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06288373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*